A recent study identifies Neural EGFL-like 2 (NELL2), a secreted protein, as a key regulator of bone homeostasis, offering potential therapeutic applications for osteoporosis. NELL2 promotes osteoblast differentiation and inhibits adipocyte formation in bone marrow stromal cells, addressing the bone remodeling imbalance in osteoporosis. The study further uncovers the molecular mechanism of NELL2’s action, revealing its activation of the focal adhesion kinase (FAK)/AKT signaling pathway through interactions with Fibronectin 1 and integrins. NELL2’s administration via adeno-associated virus (AAV) significantly improved bone density in osteoporotic mice, marking it as a promising target for clinical intervention in bone loss disorders.
Osteoporosis, a widespread bone disease affecting millions globally,…